{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:28:57Z","timestamp":1792664937652,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41391-017-0024-7","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T15:57:21Z","timestamp":1513699041000},"page":"57-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":221,"title":["Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-7546","authenticated-orcid":false,"given":"Tobias","family":"Nordstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Akre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"24_CR1","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027\u201335. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)60525-0","journal-title":"Lancet"},{"key":"24_CR2","doi-asserted-by":"publisher","first-page":"dju007","DOI":"10.1093\/jnci\/dju007","volume":"106","author":"P Stattin","year":"2014","unstructured":"Stattin P, Carlsson S, Holmstr\u00f6m B, Vickers A, Hugosson J, Lilja H, et al. Prostate cancer mortality in areas with high and low prostate cancer incidence. JNCI J Natl Cancer Inst. 2014;106:dju007\u20137. \n                    https:\/\/doi.org\/10.1093\/jnci\/dju007","journal-title":"JNCI J Natl Cancer Inst"},{"key":"24_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrurol.2009.95","volume":"6","author":"AJ Vickers","year":"2009","unstructured":"Vickers AJ, Lilja H. Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol. 2009;6:301\u20133. \n                    https:\/\/doi.org\/10.1038\/nrurol.2009.95","journal-title":"Nat Rev Urol"},{"key":"24_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.eururo.2011.12.058","volume":"61","author":"S Loeb","year":"2012","unstructured":"Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schr\u00f6der FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110\u20134. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2011.12.058","journal-title":"Eur Urol"},{"key":"24_CR5","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"S Loeb","year":"2011","unstructured":"Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186:1830\u20134. \n                    https:\/\/doi.org\/10.1016\/j.juro.2011.06.057","journal-title":"J Urol"},{"key":"24_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","volume":"147","author":"MC Benson","year":"1992","unstructured":"Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815\u20136.","journal-title":"J Urol"},{"key":"24_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/sj.pcan.4500509","volume":"4","author":"M Lujan","year":"2001","unstructured":"Lujan M, Paez A, Llanes L, Miravalles E, Berenguer A. Prostate specific antigen density. Is there a role this Parameter when screen prostate cancer? Prostate Cancer Prostatic Dis. 2001;4:146\u20139. \n                    https:\/\/doi.org\/10.1038\/sj.pcan.4500509","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"24_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/003655998750015124","volume":"32","author":"O Gustafsson","year":"1998","unstructured":"Gustafsson O, Mansour E, Norming U, Carlsson A, Tornblom M, Nyman CR. Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men. Scand J Urol Nephrol. 1998;32:373\u20137.","journal-title":"Scand J Urol Nephrol"},{"key":"24_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.urology.2017.04.015","volume":"105","author":"JS Jue","year":"2017","unstructured":"Jue JS, Barboza MP, Prakash NS, Venkatramani V, Sinha VR, Pavan N, et al. Re-examining Prostate-specific Antigen (PSA) density: defining the optimal psa range and patients for using psa density to predict prostate cancer using extended template biopsy. Urology. 2017;105:123\u20138. \n                    https:\/\/doi.org\/10.1016\/j.urology.2017.04.015","journal-title":"Urology"},{"key":"24_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","volume":"61","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61:577\u201383. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2011.11.012","journal-title":"Eur Urol"},{"key":"24_CR11","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gr\u00f6nberg","year":"2015","unstructured":"Gr\u00f6nberg H, Adolfsson J, Aly M, Nordstr\u00f6m T, Wiklund P, Brandberg Y, et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16:1667\u201376. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00361-7","journal-title":"Lancet Oncol"},{"key":"24_CR12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis and local treatment with curative intent. Eur Urol. 2017;71:618\u201329. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","journal-title":"Eur Urol"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.6004\/jnccn.2014.0120","volume":"12","author":"PR Carroll","year":"2014","unstructured":"Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, et al. Prostate cancer early detection, version 1.2014. J Natl Compr Canc Netw. 2014;12:1211\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"24_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13465","volume":"119","author":"S Washino","year":"2017","unstructured":"Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy na\u00efve patients. BJU Int. 2017;119:225\u201333. \n                    https:\/\/doi.org\/10.1111\/bju.13465","journal-title":"BJU Int"},{"key":"24_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0090-4295(00)00637-3","volume":"56","author":"WJ Catalona","year":"2000","unstructured":"Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56:255\u201360.","journal-title":"Urology"},{"key":"24_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0022-5347(17)35485-X","volume":"150","author":"MK Brawer","year":"1993","unstructured":"Brawer MK, ARAMBURU E, CHEN GL, PRESTON SD, Ellis WJ. The inability of prostate-specific antigen index to enhance the predictive value of prostate-specific antigen in the diagnosis of prostatic-carcinoma. J Urol. 1993;150:369\u201373.","journal-title":"J Urol"},{"key":"24_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF00185070","volume":"11","author":"MC Benson","year":"1993","unstructured":"Benson MC, McMahon DJ, Cooner WH, Olsson CA. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol. 1993;11:206\u201313.","journal-title":"World J Urol"},{"key":"24_CR18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/cncr.21267","volume":"104","author":"C Stephan","year":"2005","unstructured":"Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4\u2009ng\/mL. Cancer. 2005;104:993\u20131003. \n                    https:\/\/doi.org\/10.1002\/cncr.21267","journal-title":"Cancer"},{"key":"24_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bju.13437","volume":"118","author":"RW Foley","year":"2016","unstructured":"Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, et al. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int. 2016;118:706\u201313. \n                    https:\/\/doi.org\/10.1111\/bju.13437","journal-title":"BJU Int"},{"key":"24_CR20","doi-asserted-by":"publisher","first-page":"djv095","DOI":"10.1093\/jnci\/djv095","volume":"107","author":"RJ Bryant","year":"2015","unstructured":"Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. JNCI J Natl Cancer Inst. 2015;107:djv095\u20135. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv095","journal-title":"JNCI J Natl Cancer Inst"},{"key":"24_CR21","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gr\u00f6nberg","year":"2015","unstructured":"Gr\u00f6nberg H, Adolfsson J, Aly M, Nordstr\u00f6m T, Wiklund P, Brandberg Y, et al Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16:1667\u201376.","journal-title":"Lancet Oncol"},{"key":"24_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","volume":"68","author":"T Nordstr\u00f6m","year":"2015","unstructured":"Nordstr\u00f6m T, Vickers A, Assel M, Lilja H, Gr\u00f6nberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015;68:139\u201346. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2014.08.010","journal-title":"Eur Urol"},{"key":"24_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bju.13676","volume":"120","author":"S Loeb","year":"2017","unstructured":"Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, et al. Prostate health index improves multivariable risk prediction of aggressive prostate cancer. BJU Int. 2017;120:61\u20138. \n                    https:\/\/doi.org\/10.1111\/bju.13676","journal-title":"BJU Int"},{"key":"24_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815\u201322. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"24_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.juro.2017.03.130","volume":"198","author":"FA Distler","year":"2017","unstructured":"Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer H-P, Wieczorek K, et al. The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction. J Urol. 2017;198:575\u201382. \n                    https:\/\/doi.org\/10.1016\/j.juro.2017.03.130","journal-title":"J Urol"},{"key":"24_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-200","volume":"9","author":"YR Murciano-Goroff","year":"2014","unstructured":"Murciano-Goroff YR, Wolfsberger LD, Parekh A, Fennessy FM, Tuncali K, Orio PF, et al. Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014;9:200. \n                    https:\/\/doi.org\/10.1186\/1748-717X-9-200","journal-title":"Radiat Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0024-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:00Z","timestamp":1684618380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-017-0024-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1038\/s41391-017-0024-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]},"assertion":[{"value":"28 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HG and ME have patents pending related to the Stockholm3 test. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}